Keywords: chronic renal failure, sympathetic nervous It is therefore surprising that so far nephrologists have neglected the therapeutic potential of modulating system, hypertension sympathetic nervous activity in chronic renal failure. This is even more strange, since there is convincing evidence to show that in chronic renal failure sympath-
Introduction
etic overactivity is substantially involved in the development of hypertension, progression of renal failure and cardiovascular prognosis. The available experiCurrently a dramatic increase in patients with mental and clinical evidence to suggest such a pathoend-stage renal failure is seen world-wide [1, 2] .
physiological role of sympathetic overactivity is briefly Furthermore, cardiovascular morbidity and mortality summarized below. is exceedingly high in patients with chronic renal failure. Preventing progression of chronic renal failure and reducing cardiovascular complications in uraemia are major challenges to nephrologists. In the following Renal disease activates the sympathetic system we marshal evidence that sympathetic overactivity, so far a neglected aspect of renal failure, is an import-In 1992 Converse et al. [5] documented that in endant pathomechanism contributing to progression and stage renal failure sympathetic tone is increased. They cardiovascular complications. It is possible that inter-measured sympathetic nerve activity using microneurventions to interfere with sympathetic overactivity will ography of the N. peronaeus and demonstrated an provide new therapeutic approaches.
increased sympathetic firing rate even in the intradialytic interval suggesting that this finding was largely volume independent. The most surprising observation
The sympathetic nervous system in cardiovascular was that bilaterally nephrectomized patients had disease and chronic renal failure normal sympathetic drive-comparable to that of controls without renal failure. These patients also had In chronic renal disease, the two most important lower blood pressure. The authors concluded that the progression factors which are susceptible to interven-diseased kidneys activate the sympathetic system. This tion are hypertension and proteinuria. In this respect could imply that the sympathetic nervous system plays research and therapy in the past focused mainly on an important role in renal disease-but what are the interventions concerning the renin-angiotensin-system. underlying mechanisms? Many controlled studies have demonstrated that ACE-
The kidneys have a dense afferent sensory and inhibitors, compared to placebo, attenuate the rate of efferent sympathetic innervation. Therefore, they can progression of chronic renal failure. There is still debate be origin as well as target of overactivity of the whether the beneficial effect of ACE-inhibition is fully sympathetic nervous system ( Figure 1 ). This has been explained by better control of blood pressure [3] . The shown convincingly in an animal model of chronic sympathetic nervous system is known to be important renal failure [6 ] . Subtotally nephrectomized rats for pathophysiology and prognosis of a variety of develop a rapid increase of blood pressure within 1 cardiovascular diseases including essential hyperten-week after renal ablation. In contrast, subtotally sion and chronic heart failure. For instance, the degree nephrectomised rats in which afferent sensory signals of sympathetic overactivity is a major predictor of have been abrogated by section of the dorsal roots do survival in patients with a history of myocardial infarc-not develop hypertension. This observation suggests, tion and determines the risk of arrhythmia and sudden that afferent signals from the diseased kidneys are cardiac death [4] .
transmitted to the vasomotor control center in the brain and thereby increase blood pressure ( Figure 1 ) at least in this model of chronic renal failure. suffering from chronic renal failure? The answer seems to be yes! Ligtenberg and colleagues [7] used the same autosomal dominant polycystic kidney disease [13] despite normal renal function. These results suggest microneurographic technique and demonstrated that even patients who are not yet on dialysis had increased that sympathetic overactivity is an early event in the pathophysiology of chronic renal failure and that renal sympathetic nerve activity as well. What are the mechanisms in the kidney provoking afferent renal nerve damage of various aetiologies activates the sympathetic nervous system via afferent signal of sensory renal traffic? It is conceivable that uraemic toxins act as irritants, but this possibility seems unlikely for various nerves (Figure 1) .
The resulting overactivity at the neuroeffector juncreasons. First, even after correction of uraemia by renal transplantation increased sympathetic nerve tion of peripheral organs has important cardiovascular consequences. Enhanced sympathetic neurotransmitter activity persists [8] . Second, even acute renal damage [9] and renal ischaemic disease [10,11], not associated release aggravates hypertension and leads to cardiac hypertrophy. Both events may explain at least in part with uraemia, lead to sympathetic activation and hypertension. Furthermore, increased noradrenaline the high cardiovascular mortality of patients with chronic renal failure, analogous to the deleterious effect secretion rates have been observed in patients with nephrotic syndrome [12] and in hypertensive of high sympathetic tone after myocardial infarction.
Moreover, in uraemic patients survival after myocard-these levels any further [17] .
compatible with the notion that enhanced release after myocardial infarction as compared to 80% of diabetic patients without nephropathy [4] . It is possible of noradrenaline and other neurotransmitters is an important pathomechanism of progressive glomerulothat an imbalance between the sympathetic and parasympathetic nervous system aggravates the effect of sclerosis (Figure 1) at least in the ablation model of chronic renal failure. It is interesting to note, that in sympathetic overactivity [14, 15] . A lack of vagal influence in patients with diabetic nephropathy has been chronic renal failure patients the ACE inhibitor enalapril was able to reduce central sympathetic overactivity shown by analysis of heart rate variability [14, 15] and by acetylcholine release studies of human cardiac tissue measured by microneurography when given chronically [7] . Since enalapril does not readily penetrate into the in vitro [16 ] . central nervous system it is possible, that the release of neurotransmitters within the kidney is modulated by ACE-inhibitors leading to reduce afferent signalling
Can one slow progression of renal failure by
to the vasomotor center in the brain.
inhibiting sympathetic tone?
Taken together, it appears too early to generally recommend sympatholytic drugs for patients with chronic renal failure. Nevertheless mitigation of symAs discussed above, sympathetic overactivity is present in chronic renal failure. It could be shown that renal pathetic overactivity does not only slow progression of renal disease; previous studies also documented that noradrenaline release is enhanced by more than 30% in kidney cortex of subtotally nephrectomized rats sympatholytic drugs are extremely effective in lowering blood pressure in patients with chronic renal failure [17] . Growth factors ( TGF-b, PDGF, angiotensin II ) as well as sympathetic neurotransmitters are able to [7, 27] . Autonomic dysfunction with an imbalance between parasympathetic and sympathetic nervous directly stimulate DNA-synthesis and proliferation of tubular, glomerular epithelial and smooth muscle cells function is documented in end-stage renal failure and this apparently contributes to the high cardiovascular [18] [19] [20] . In progression of renal failure renal growth plays an important permissive role. Together with its morbidity and mortality [14] [15] [16] . Thus, one would expect that patients with chronic renal failure will cotransmitters neuropeptide Y and ATP [21, 22] noradrenaline may induce growth by activation of receptor benefit from inhibition of sympathetic overactivity. mediated signalling cascades in chronic renal failure.
If enhanced renal neurotransitter release is involved in References the development of glomerulosclerosis, then inhibition of sympathetic nerve activity would be expected to 
